Pruritus Treatment Market Size and Trends by Drug Type, Disease Type, Distribution Channel, and Region

Pruritus Treatment Market size was valued at USD 8.45 Bn. in 2023 and is expected to grow at a CAGR of 3.4% from 2024 to 2030 to reach USD 10.68 Bn.
Global Pruritus Treatment Market Overview
Pruritus is commonly known as itchiness. It is an uncomfortable sensation in the skin that triggers an urge to scratch. Chronic pruritus is the itching that persists past six weeks. It is caused by several factors such as systemic diseases, nerve disorders, skin diseases, psychological conditions, and irritation. Sensile pruritus, Brachioradial pruritus, Nocturnal pruritus, Uremic pruritus, and Pruritus ani are different types of pruritus based on itching in different parts of the body and age groups. Most generally pruritus is caused by contact with an irritant such as chemicals or certain fabrics.

Pruritus treatment focuses on breaking the itch-scratch cycle by keeping the skin hydrated and treating it with oral and topical medications. For each person, the treatment for pruritus is unique and varies based on what caused the symptoms. As per the study, the Pruritus Treatment Market is expected to grow during the forecast period.To know about the Research Methodology :- Request Free Sample Report
Pruritus Treatment Market Dynamics
Pruritus is a dermatologic problem that increases commonly in incidence with age. In some patients, the condition is so severe that it affects the quality of life. People who suffer from pruritus suffer from the itch that rashes, which leads to depression, sleep disruption and anxiety. Hence the growing adult population and its severe effects on patients are the factors mainly driving the Pruritus Treatment Market growth. Notalgia Paresthetica (NP) is an under-recognized but common chronic sensory neuropathy affecting the upper back. It is estimated that 8 percent of chronic pruritus patients suffer from neuropathic itch. This drives the demand for the pruritus treatment. People receiving cytotoxic chemotherapy, radiation therapy and biologic response modifiers for the treatment of malignancy mostly experience pruritus.

This same population is also mostly exposed to several etiologic factors relating to pruritus ranging from nutrition-related xerosis (dry skin) to radiation desquamation, biologic agent-induced and chemotherapy-induced side effects, antibiotic reactions and other drug sensitivities. Therefore, the increasing population receiving these therapies is driving the growth of the market. The rising awareness of new therapies and increasing investments in the healthcare sector are expected to create various growth opportunities for the market.

Hemodialysis treats pruritus associated with chronic kidney disease, which is common in patients. According to the International Dialysis Outcomes and Practice Patterns Study, 26% to 48% of the patients receiving hemodialysis were at least moderately bothered by the itchy skin. This is expected to drive the Pruritus Treatment Market during the forecast period.

High-potency steroids are majorly prescribed but are associated with safety risks if used for the long term. In 2022, the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of moderate to severe atopic dermatitis in children 12 years of age and adults. It also causes serious side effects such as serious infections, increases risk of death in people 50 years and older with at least 1 heart disease risk factor and cancer and immune systems problems. This creates fear among patients because of which they avoid treatment, which affects the growth of the market.
Pruritus Treatment Market Regional Insights
The Pruritus Treatment Market in North America held the major share of the global market in 2023. This is attributed to the large number of adults in the US living with prurigo nodularis and most of them were in need of new treatment options. The presence of major players in the region highly investing in research and development is providing various opportunities for the growth of the regional market. The increasing healthcare expenditure is also contributing to the market growth. The US Budget provides USD 663 million toward opioid use disorder prevention and treatment programs, including programs authorized in the Jason Simcakoski Memorial and Promise Act.

Asia Pacific Pruritus Treatment Market is expected to grow at a high rate during the forecast period majorly due to the growing population having a huge adult population suffering from several diseases. Difelikefalin received EMA approval for the treatment of moderate to severe pruritus associated with chronic kidney disease in adults treated by hemodialysis in April 2022. This is the only other treatment approved for chronic kidney disease–associated pruritus in Japan. The increasing research and development for the treatment of pruritus is expected to drive the regional market in the future.

The increasing healthcare expenditure in the region is also contributing to the growth of the market. The Indian Union Budget allocated Rs 89,155 crore to the Ministry of Health, which is a 3.4 increase in comparison to 2022. The health sector in the country is witnessing an increase in access to patients and citizens through the launch of digital health and mental health programs.
Pruritus Treatment Market Segment Analysis 
Based on Drug Type: The segment is divided into Corticosteroids, Antihistamines, Local Anaesthetics, Immunosuppressant and others. The Corticosteroids held the largest Pruritus Treatment Market share of the market in 2023 and are expected to grow at a high rate during the forecast period. The demand for corticosteroid drugs is increasing because of the growing geriatric population suffering from pruritus. During the forecast period, the Antihistamines segment is also expected to grow rapidly due to its increase in use to treat skin allergies across the globe.

Based on Disease Type: The segment is divided into Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria and others. The Atopic Dermatitis segment held the largest Pruritus Treatment Market share in 2023. It is the most common chronic pruritic inflammatory dermatosis affecting up to 12 percent of children and 2-10 percent of adults across the world. Moderate to severe chronic pruritus is one of the defining features of Atopic Dermatitis.

Based on Distribution Channel: The segment is divided into Hospitals, Drug Stores, Pharmacies and Online Providers. The Drug Stores segment dominated the Pruritus Treatment Market by holding the largest share in 2023 and is expected to grow rapidly during the forecast period. This growth is attributed to the increasing demand for drugs for the treatment of pruritus. The Online Providers segment is expected to grow at a high rate during the forecast period. Online orders of medicines and doctor providing consulting services online helps patients to recover easily in less time by taking a rest at home. These technological developments are driving the growth of the segments.
Pruritus Treatment Market Competitive Landscape
This section of the report includes a list of Pruritus Treatment key competitors with their global presence, financial information, technological developments, etc. SWOT analysis was employed to provide the strengths and weaknesses of the key players in the Pruritus Treatment Industry. The companies are investing in research and development to provide advanced therapies to people and to develop and manufacture healthcare products.

Galderma is the leading company dedicated to advancing the future of dermatology. In March 2023, it premiered the positive results of phase III from OLYMPIA 2 trial evaluating the safety, efficiency, pharmacokinetics and immunogenicity of nemolizumab. The phase III OLYMPIA 2 trial showed nemolizumab monotherapy significantly improved pruritus (itch) and skin lesions.

In 2022, Regeneron Pharmaceuticals, Inc. and Sanofi confirmed the approval of Dupixent® (dupilumab) by the Food and Drug Administration (FDA) for the treatment of adult patients with prurigo nodularis. The medicine specifically indicated to treat prurigo nodularis in the US.

Cara Therapeutics is a commercial-stage biopharmaceutical company whose KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The company has phase 3 programs and developing an oral formulation of diflikefalin for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis.
Pruritus Treatment Market Scope: Inquire before buying



Global Pruritus Treatment Market


Report Coverage
Details


Base Year:
2023
Forecast Period:
2024-2030


Historical Data:
2018 to 2023
Market Size in 2023:
US $ 8.45 Bn.


Forecast Period 2024 to 2030 CAGR:
3.4%
Market Size in 2030:
US $ 10.68 Bn.


 Segments Covered:
By Drug Type
Corticosteroids
Antihistamines
Local Anaesthetics
Immunosuppressant
others


By Disease Type
Atopic Dermatitis
Allergic Contact Dermatitis
Urticaria
others


By Distribution Channel
Hospitals
Drug Stores
Pharmacies
Online Providers



Pruritus Treatment Market Regional Insights:
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Pruritus Treatment Market Key Players
1. AbbVie Inc.
2. Amgen Inc.
3. Cara therapeutics
4. Galderma S.A.
5. MC2 therapeutics
6. Regeneron Pharmaceuticals
7. Pfizer Inc.
8. Sanofi
9. Bausch Health Companies Inc.
10. Leo Pharma A/S
11. GlaxoSmithKline plc (GSK)
Frequently Asked Questions
1] What is the expected CAGR of the Global Pruritus Treatment Market during the forecast period?
Ans. During the forecast period, the Global Pruritus Treatment Market is expected to grow at a CAGR of 3.4 percent.

2] What was the Pruritus Treatment Market size in 2023?
Ans. USD 8.45 Bn was the Pruritus Treatment Market size in 2023.

3] What is the expected Pruritus Treatment Market size by 2030?
Ans. USD 10.68 Bn is the expected Pruritus Treatment Market size by 2030.

4] What are the major Pruritus Treatment Market segments?
Ans. The market is divided by Drug Type, Disease Type and Distribution Channel

5] Which region’s Pruritus Treatment Market share is expected to increase at a high rate during the forecast period?
Ans. Asia Pacific Pruritus Treatment Market share is expected to increase at a high rate during the forecast period.